News & Events

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

Image-empty-state.png

27 January 2022

Read More

HaemaLogiX welcomes Tertia Dex to the team

Image-empty-state.png

17 January 2022

Read More

HaemaLogiX welcomes Professor Simon Harrison to the SAB

Image-empty-state.png

21 December 2021

Read More

Full presentation materials on the novel antigens LMA and KMA at the 63rd annual ASH meeting are now available

Image-empty-state.png

15 December 2021

Read More

Dr Mary Sartor to present research on LMA and the 10B3 monoclonal antibody developed by HaemaLogiX at ASH 2021

Image-empty-state.png

5 November 2021

Read More

Platinum leads immuno-oncology company HaemaLogiX’s $10m capital-raising round

Image-empty-state.png

12 September 2021

Read More

HaemaLogiX raises $10 million to advance multiple myeloma treatments

Image-empty-state.png

8 September 2021

Read More

HaemaLogiX announces collaboration with the Peter MacCallum Cancer Centre

Image-empty-state.png

5 February 2021

Read More

Orphan Drug Designation for KappaMab transferred to HaemaLogiX

Image-empty-state.png

29 January 2021

Read More

HaemaLogiX announces issuance of Australian patent for LMA

Image-empty-state.png

22 January 2021

Read More

HaemaLogiX Announces the Outcomes of Two Innovation Connections Grant Projects

Image-empty-state.png

16 October 2020

Read More

Bryce Carmine to present at AusBiotech & Invest 2020

Image-empty-state.png

9 October 2020

Read More